aTyr Pharma Competitors and Similar CompaniesClear all
aTyr Pharma's competitors and similar companies include Aerie Pharmaceuticals, Catalyst Pharmaceuticals, scPharmaceuticals and Merus.
 Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |  Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. |  scPharmaceuticals scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. | ||
Founding Date | Founding Date 2005 | Founding Date 2005 | Founding Date 2002 | Founding Date 2014 | Founding Date 2003 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | Locations Coral Gables, US HQ | Locations Burlington, US HQ | Locations Utrecht, NL HQ Cambridge, US |
Employees | Employees 4235% decrease | Employees 3808% increase | Employees 7649% increase | Employees 96256% increase | Employees 260 |
Valuation ($) | Valuation ($) 131.1 m | Valuation ($) 722.2 m | Valuation ($) 2.6 b | Valuation ($) 221.6 m | Valuation ($) 3.6 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $190k (FY, 2025) | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $589m (FY, 2025) | Revenue (est.) $36.3m (FY, 2024) | Revenue (est.) $36.1m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) | Cost of goods $87.3m (FY, 2025) | Cost of goods $11.4m (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $501.7m (FY, 2025) | Gross profit $25m (FY, 2024) | Gross profit $36.1m (FY, 2024) |
Net income | Net income ($74.1m) (FY, 2025) | Net income ($74.8m) (FY, 2021) | Net income $214.3m (FY, 2025) | Net income ($85.1m) (FY, 2024) | Net income ($215.3m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 388.6m | Total funding raised N/A | Total funding raised $ 62.5m | Total funding raised $ 149.3m |
For sources of this data, please see the company profile
View Company Profiles
Aerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View companyCatalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View companyscPharmaceuticals
HQ
Burlington, US
Employees
96
scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.
View companyMerus
HQ
Utrecht, NL
Employees
260
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View company